Cellectis S.A. (CLLS)
NASDAQ: CLLS
· Real-Time Price · USD
1.47
-0.05 (-3.31%)
At close: May 23, 2025, 3:58 PM
1.49
1.36%
After-hours: May 23, 2025, 07:35 PM EDT
-3.31% (1D)
| Bid | 1.41 |
| Market Cap | 145.76M |
| Revenue (ttm) | 41.51M |
| Net Income (ttm) | -36.76M |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | -2.19 |
| Forward PE | -1.47 |
| Analyst | Buy |
| Ask | 1.51 |
| Volume | 48,119 |
| Avg. Volume (20D) | 322,592 |
| Open | 1.51 |
| Previous Close | 1.52 |
| Day's Range | 1.46 - 1.60 |
| 52-Week Range | 1.10 - 2.91 |
| Beta | 3.28 |
About CLLS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLLS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts10 months ago
+12.2%
Cellectis shares are trading higher after the comp...
Unlock content with
Pro Subscription
10 months ago
+0.49%
Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.
